Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers.

Pharmacogenetics and genomics - 1 Aug 2012

Cho Sung Kweon, Oh Eun Sil, Park Kyungsoo, Park Min Soo, Chung Jae Yong

Abstract excerpt

OBJECTIVE: We investigated whether the UGT1A3 polymorphisms play an important role in interindividual variations in atorvastatin lactonization and lipid-lowering effect. METHODS: Twenty-three healthy volunteers were administered atorvastatin 20 mg once daily for 14 days. Serum levels of lipids we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrroles
Share to Area Under Curve
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to Glucuronosyltransferase

Share to Heptanoic Acids

Share to Lactones

Share to Lipid Metabolism

Source

Identifiers

PMID: 22555810
DOI: 10.1097/FPC.0b013e3283544085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22555810-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers.PMID 22555810Read ↗

UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In VivoSemantic proximity Read ↗

Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

Statin Lactone Metabolism is a Determinant of 5-year Cardiovascular Outcomes Independent of Serum CholesterolSemantic proximity Read ↗

Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.Semantic proximity Read ↗

UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.Semantic proximity Read ↗

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.Semantic proximity Read ↗

Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.Semantic proximity Read ↗

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.Semantic proximity Read ↗

Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.Semantic proximity Read ↗

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.